Table 3.
Relationship between participant characteristics and adverse reactions.
| Adverse reactions after the 1st dose |
Adverse reactions after the 2nd dose |
|||||
|---|---|---|---|---|---|---|
| (−) | (+) | P value | (−) | (+) | P value | |
| Number of participants (%) | 245 (38.1) | 398 (61.9) | 115 (18.3) | 514 (81.7) | ||
| Age, years | 44.3 ± 11.3 | 43.9 ± 10.5 | 0.619 | 46.9 ± 11.0 | 43.5 ± 10.7 | 0.001 |
| Female sex (%) | 157 (64.1) | 303 (76.1) | 0.001 | 65 (56.5) | 384 (74.7) | <0.001 |
| BMI, kg/m2 | 21.8 ± 2.9 | 21.9 ± 3.3 | 0.698 | 22.2 ± 3.2 | 21.8 ± 3.1 | 0.211 |
| Pre-vaccination antibody titer, AU/mL | 5.5 ± 34.1 | 12.6 ± 132.5 | 0.409 | 9.5 ± 51.4 | 10.2 ± 116.4 | 0.951 |
| Systemic steroid use (%) | 2 (0.8) | 5 (1.3) | 0.714 | 0 (0) | 6 (1.2) | 0.598 |
| Other immuno-suppressant use (%) | 1 (0.4) | 10 (2.5) | 0.059 | 2 (1.7) | 8 (1.6) | 1.000 |
| History of immunodeficiency (%) | 0 (0) | 1 (0.3) | 1.000 | 0 (0) | 1 (0.2) | 1.000 |
| History of malignancy (%) | 6 (2.5) | 6 (1.5) | 0.388 | 3 (2.6) | 9 (1.8) | 0.467 |
| History of autoimmune diseases (%) | 5 (2.0) | 12 (3.0) | 0.615 | 2 (1.7) | 14 (2.72) | 0.749 |
| History of diabetes (%) | 2 (0.8) | 2 (0.5) | 0.638 | 1 (0.87) | 3 (0.58) | 0.555 |
| History of COVID-19 (%) | 3 (1.2) | 6 (1.5) | 1.000 | 3 (2.6) | 6 (1.2) | 0.213 |
| History of COVID-19-like illness (%) | 20 (8.2) | 39 (9.8) | 0.574 | 14 (12.3) | 44 (8.6) | 0.213 |
| History of close contact with COVID-19 patients (%) | 12 (4.9) | 6 (1.5) | 0.014 | 4 (3.5) | 14 (2.7) | 0.550 |
BMI, body mass index; COVID-19, coronavirus disease.